DOCSLIB.ORG

Jan. 16, 2019 'NIGHTLINE'-PRODUCED

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Jan. 16, 2019 'NIGHTLINE'-PRODUCED Jan. 16, 2019 ‘NIGHTLINE’-PRODUCED DOCUMENTARY, ‘THE DROPOUT,’ EXAMINES THE RISE AND FALL OF ELIZABETH HOLMES, FOUNDER AND CEO OF THERANOS, HER COMPANY ONCE VALUED AT NEARLY $10 BILLION Presented by Rebecca Jarvis, Documentary Features New Interviews and Never-Before-Aired Deposition Tapes ‘Nightline’ Airs Special Preview and ABC Radio Launches Six-Episode Podcast of the Same Title on Wednesday, Jan. 23 After a three-year investigation by ABC News Chief Business, Technology and Economics correspondent Rebecca Jarvis, “Nightline” has produced the feature documentary “The Dropout” to tell the story of Elizabeth Holmes, the college dropout turned founder and CEO of technology company Theranos. Once the youngest self-made female billionaire, Elizabeth’s company and its nearly $10 billion valuation came crashing down amid accusations of massive fraud. In “The Dropout,” Jarvis guides viewers through the twists and turns of Elizabeth’s rise and fall with new interviews and never-before-aired deposition tapes, and hears from central figures from all chapters of the story. On Wednesday, Jan. 23, “Nightline” will air a special preview of the documentary; and ABC Radio will launch a six-part podcast with the same title, also hosted by Jarvis. New podcast episodes will be made available each Wednesday. “The Dropout” features the first sit-down interview with Jeff Coopersmith, the attorney representing Ramesh “Sunny” Balwani, former Theranos president and COO, and exclusive access to never-before-aired deposition tapes of key players including Elizabeth; Balwani; Christian Holmes, Elizabeth’s brother; Tyler Shultz, Theranos whistleblower; Theranos board members Bill Frist, Gary Roughead, Robert Kovacevich and more. Also featured are Jarvis’ exclusive broadcast interviews with Sheri Ackert and Pallav Sharda, patients speaking out about what they say are inaccurate test results they received through Theranos, plus Elizabeth’s high school physics teacher, former Apple executive and Theranos board member Avie Tevanian, and dozens of former employees, investors and journalists. “This is a story that I’ve been deeply researching and investigating for years,” says Jarvis. “I’ve been covering business for more than a decade, from the housing collapse to the fall of Bear Stearns and the Bernie Madoff scandal. But none of these comes even close to the mystery and intrigue of Elizabeth Holmes. I’m excited to share the information we’ve gathered both in the documentary and the six-part podcast.” Theranos was created by Elizabeth, a Stanford University dropout, and was characterized as a revolutionary technology company capable of performing hundreds of blood tests and detecting diseases by utilizing a drop or two of blood. But following a 2015 investigative piece published in the Wall Street Journal questioning the company’s validity, Theranos began to disintegrate. Elizabeth and Balwani were charged with “massive fraud” by the U.S. Securities and Exchange Commission (SEC). The U.S. Department of Justice alleges they perpetrated multimillion dollar schemes to defraud investors, doctors and patients – they have both pleaded not guilty but face up to 20 years in prison if convicted. Just last year Elizabeth reached a settlement with the SEC, which included a $500,000 fine. She was stripped of her control of the company and is now barred from serving as an officer or director of a public company for 10 years. Theranos and Elizabeth neither admitted nor denied the allegations in the SEC’s complaint. “The Dropout” is a documentary film by Victoria Thompson, Taylor Dunn and Ashley Louszko, and a podcast written and reported by Dunn, Jarvis and Senior Producer Thompson. Steven Baker is executive producer and Jenna Millman is supervising producer. “The Dropout” podcast is available on Apple Podcasts, Google Podcasts, TuneIn, Spotify, Stitcher and the ABC News app. VIDEO TRAILER: https://abcn.ws/2QSGkwt EMBED: <iframe src="https://abcnews.go.com/video/embed?id=undefined" width="640" height="360" scrolling="no" style="border:none;" allowfullscreen></iframe> PODCAST TRAILER: https://bit.ly/2AXQS8D EMBED: <iframe src="https://tunein.com/embed/player/p1185139/" style="width:100%; height:100px;" scrolling="no" frameborder="no"></iframe> LOGO: https://bit.ly/2Dc7ZoC PRESS RELEASE: https://bit.ly/2Fv93Gy TWEET: https://ctt.ac/ucoUd ABC News Media Relations Curt Villarosa (212) 456-3742 [email protected] Elizabeth Russo (212) 456-7414 [email protected] For more information, follow ABC News PR on Facebook, Twitter and Instagram. -- ABC -- .
Load more

Recommended publications
  • Theranos As a Legal Ethics Case Study
    Vanderbilt University Law School Scholarship@Vanderbilt Law Vanderbilt Law School Faculty Publications Faculty Scholarship 2021 How and Why Did It Go So Wrong?: Theranos as a Legal Ethics Case Study G. S. Hans Follow this and additional works at: https://scholarship.law.vanderbilt.edu/faculty-publications Part of the Legal Education Commons, and the Legal Ethics and Professional Responsibility Commons DATE DOWNLOADED: Mon May 24 12:25:08 2021 SOURCE: Content Downloaded from HeinOnline Citations: Bluebook 21st ed. G. S. Hans, How and Why Did It Go So Wrong?: Theranos as a Legal Ethics Case Study, 37 GA. St. U. L. REV. 427 (2021). ALWD 6th ed. Hans, G. G., How and why did it go so wrong?: Theranos as a legal ethics case study, 37(2) Ga. St. U. L. Rev. 427 (2021). APA 7th ed. Hans, G. G. (2021). How and why did it go so wrong?: Theranos as legal ethics case study. Georgia State University Law Review, 37(2), 427-470. Chicago 17th ed. G. S. Hans, "How and Why Did It Go So Wrong?: Theranos as a Legal Ethics Case Study," Georgia State University Law Review 37, no. 2 (Winter 2021): 427-470 McGill Guide 9th ed. G S Hans, "How and Why Did It Go So Wrong?: Theranos as a Legal Ethics Case Study" (2021) 37:2 Ga St U L Rev 427. AGLC 4th ed. G S Hans, 'How and Why Did It Go So Wrong?: Theranos as a Legal Ethics Case Study' (2021) 37(2) Georgia State University Law Review 427. MLA 8th ed.
    [Show full text]
  • Squaring Venture Capital Valuations with Reality ONLINE APPENDIX
    Squaring Venture Capital Valuations with Reality ONLINE APPENDIX Will Gornall Sauder School of Business, University of British Columbia Ilya A. Strebulaev Graduate School of Business, Stanford University and National Bureau of Economic Research Sept 2017 Find the full paper here: https://papers.ssrn.com/sol3/papers.cfm?abstract_id=2955455 The online appendix follows. Appendix A contains the alternative names for the unicorns in our sample. Appendix B lists companies whose COIs omit information. Appendix C lists companies where we could not locate the most recent COI. Appendix D contains examples of legal text for each of the major terms. Appendix E details the major terms we found for each company in our sample. Appendix F contains comparative statics. Appendix G contains discussion of our return distribution assumptions. Appendix A: Full Legal Names and Other Names for Unicorns in Our Sample Short Name Legal Name Also Known As 23andMe 23andMe, Inc. A123 Systems A123 Systems, Inc. B456 Systems Actifio Actifio, Inc. Adaptive Biotech Adaptive Biotechnologies Adaptive TCR Corporation Age of Learning Age of Learning, Inc. Airbnb Airbnb, Inc. Airbed & Breakfast, Inc Anaplan Anaplan, Inc. AppDirect AppDirect, Inc. Origo Networks Corporation AppDynamics AppDynamics, Inc. Singularity Technologies, Inc. Appnexus AppNexus Inc. Apttus Apttus Corporation Automattic Automattic Inc. Avant Avant, Inc. Avant Credit Corporation Better Place Better Place, Inc. Better Place Holdings; Better PLC Bloom Energy Bloom Energy Corporation Bloom Energy Server; Ion America Corporation Bloom Energy Bloom Energy Corporation Ion America Corporation Blue Apron Blue Apron, Inc. Petridish Media, Inc. Box Box, Inc. Box.Net Buzzfeed BuzzFeed, Inc. Carbon3D Carbon3D, Inc. EIPI Systems, Inc.
    [Show full text]
  • The Effect of FOMO on Stakeholder Enrollment
    The Effect of FOMO on Stakeholder Enrollment Susan L. Young, PhD Kennesaw State University Kennesaw, GA Ph: 470-578-4536 [email protected] Birton Cowden, PhD Kennesaw State University Kennesaw, GA Ph: 470-578-36781 [email protected] 1 The Effect of FOMO on Stakeholder Enrollment Abstract Stakeholder theory suggests dishonest ventures would struggle with stakeholder enrollment, limiting resource access and ultimately failing. Yet cases exist where amoral entrepreneurs do enroll stakeholders through deceit. We propose “fear of missing out” on an opportunity facilitates enrollment by encouraging stakeholder acceptance of information asymmetry. To illustrate we use exemplar Theranos: a biotech firm which convinced stakeholders it would revolutionize healthcare, rising to a $10 billion valuation through 15 years of sustained deceit. We contribute to theory by demonstrating the dark side of stakeholder enrollment, where opportunism increases venture power over stakeholders, and deceit can endure long past start up. Keywords: stakeholder theory, stakeholder enrollment, entrepreneurial deceit, fear of missing out, legitimacy 2 The Effect of FOMO on Stakeholder Enrollment “Theranos had demonstrated a commitment to investing in and developing technologies that can make a difference in people’s lives, including for the severely wounded and ill. I had quickly seen tremendous potential in the technologies Theranos develops, and I have the greatest respect for the company’s mission and integrity.” (Johnson, 2015) — 4-star General Jim Mattis, U.S. Marine Corps, Retired U.S. Secretary of Defense, 2017-2019 The Securities and Exchange Commission today charged Silicon Valley-based private company Theranos Inc., its founder and CEO Elizabeth Holmes, and its former President Ramesh “Sunny” Balwani with raising more than $700 million from investors through an elaborate, years-long fraud in which they exaggerated or made false statements about the company’s technology, business, and financial performance.
    [Show full text]
  • Debates9 963919 9878034 Final Group Paper
    Group 9 Against Edison- Potential Patients Kendall Travis, Charles Goff, Jenna Lang, Isaiah Watts Position: Against Edison Perspective: Potential Patients Strategy: Against Edison- Potential Patients Background As appealing as Theranos’s low prices are for blood testing, the cost of that is results that are far from the truth. The lab technicians who work at Theranos have little faith in the tests that they do. They feel criminal, uncertain, and concerned enough to the point where they would never do a test there or allow a family member to. For anyone to work there, non-disclosure agreements have to be signed. Clearly the company is hiding something. And for the many workers who have quit Theranos, they have spoken up about how defective everything is there, knowing it would result in the harassment and hounding from Theranos’s team of lawyers and higher up individuals, a price they were willing to pay to warn potential patients like us. The life-changing effects of Theranos’s work have all been anecdotal claims from Elizabeth Holmes, her work is discovered in isolation, and also her work is impossible to achieve with a single drop of blood according to medical experts. All of these are signs of bogus science that can be tied to Theranos. The list of concerns we have compiled comes from watching The Inventor: Out for Blood in Silicon Valley on HBO. The documentary alone has made it easy for us, as potential patients, to see that Theranos is a fraudulent and unfit company that is unethical for any patient to go to.
    [Show full text]
  • UPDATED 09.20.12 WNET Amgradday CPB Fact Sheet Nat'l
    Contact: Donna Williams WNET New York Public Media 212-560-8030; [email protected] American Graduate Day Web site: www.americangraduate.org/grad-day American Graduate Day Fact Sheet Program Title: American Graduate Day Airdate: Saturday, September 22, 2012 from 1:00-8:00 pm ET on public television Program description: American Graduate Day Presented by WNET and Public Radio Exchange (PRX ), American Graduate Day is a multi-platform event featuring a live television broadcast, radio playlist with premiere documentaries, and participation from more than 20 national partner organizations, celebrities and athletes to spotlight solutions to the nation’s dropout crisis in which one in four students do not finish high school. Viewers and listeners will be encouraged to become an “American Graduate Champion” by offering their time, donating resources, connecting with the organizations on social media or learning more about the crisis. With special guests including Michael Powell, representing America’s Promise Alliance , and PBS NewsHour senior correspondent Ray Suarez, the national television broadcast will air live on public television stations from the Tisch WNET Studios at Lincoln Center from 1:00 to 8:00 p.m. EST on Sept. 22 (check local listings). Participating public television stations around the country will take the live feed and have an opportunity to add local content to support the national broadcast. American Graduate Day highlights community partners, educators and youth, who help keep at-risk students in school, across the nation. Each community partner profiled will provide viewers with information on how to become involved with American Graduate and the featured organizations.
    [Show full text]
  • Theranos' Bad Blood
    Theranos’ Bad Blood In 2003, Stanford University student Elizabeth Holmes founded the health care company Theranos. The goal of the company was to revolutionize health care. Beginning with the goal of creating a patch to deliver drugs, the company instead shifted focus to developing a simple and effective method for blood diagnosis. Holmes dropped out of Stanford and began raising millions of dollars in funding. The company claimed that its technology could offer over 240 tests from just a prick of the finger. Test results could be delivered to a patient’s phone in hours, and a single test would cost less than half of the reimbursement rate of Medicare and Medicaid. Blood could be diagnosed easily without the need for many vials of blood drawn from patients’ veins or expensive lab work. By 2014, the company was valued at $9 billion, of which Holmes held a majority stake. Many investors backed the company based on the promise of the technology. Holmes received glowing profiles in news magazines, was featured on television shows, and presented keynote addresses at tech conferences. But the excitement of investors and the promise of the technology did not translate into success. Operating largely in a cloak of secrecy, the company could never validate its claims about its blood sampling technology, and many of its lab results went unchecked. In 2015, journalist John Carreyrou investigated the company for an article in The Wall Street Journal. He disclosed problems in the company’s equipment and testing methods. He found that the company did not even use its own technology in tests and often relied on older technology from other companies.
    [Show full text]
  • Private Company Lies
    Private Company Lies ELIZABETH POLLMAN* Rule 10b±5's antifraud catchall has been called one of the most conse- quential pieces of American administrative law and one of the most highly developed areas of judicially created federal law. Although the Rule broadly prohibits securities fraud in both public and private com- pany stock, the vast majority of jurisprudence, and the voluminous aca- demic literature that accompanies it, has developed through a public company lens. This Article illuminates how the explosive growth of private markets has left huge portions of U.S. capital markets with relatively light secur- ities fraud scrutiny and enforcement. Some of the largest private compa- nies by valuation grow in an environment of extreme information asymmetry and with the pressure, opportunity, and rationalizing culture that can foster misconduct and deception. Many investors in the private markets are sophisticated and can bear high levels of risk and signi®cant losses from securities fraud. It is increasingly evident, however, that pri- vate company lies can harm a broader range of shareholders and stake- holders as well as the ef®ciency of allocating billions of dollars for innovation and new business. In response to this underappreciated prob- lem, this Article explores a range of mechanisms to improve accountabil- ity in the private markets and ultimately argues for greater public oversight and enforcement. TABLE OF CONTENTS INTRODUCTION ..................................................... 354 I. THE DEVELOPMENT OF RULE 10B±5 IN A
    [Show full text]
  • THE NATIONAL ACADEMY of TELEVISION ARTS & SCIENCES ANNOUNCES NOMINATIONS for the 44Th ANNUAL DAYTIME EMMY® AWARDS
    THE NATIONAL ACADEMY OF TELEVISION ARTS & SCIENCES ANNOUNCES NOMINATIONS FOR THE 44th ANNUAL DAYTIME EMMY® AWARDS Daytime Emmy Awards to be held on Sunday, April 30th Daytime Creative Arts Emmy® Awards Gala on Friday, April 28th New York – March 22nd, 2017 – The National Academy of Television Arts & Sciences (NATAS) today announced the nominees for the 44th Annual Daytime Emmy® Awards. The awards ceremony will be held at the Pasadena Civic Auditorium on Sunday, April 30th, 2017. The Daytime Creative Arts Emmy Awards will also be held at the Pasadena Civic Auditorium on Friday, April 28th, 2017. The 44th Annual Daytime Emmy Award Nominations were revealed today on the Emmy Award-winning show, “The Talk,” on CBS. “The National Academy of Television Arts & Sciences is excited to be presenting the 44th Annual Daytime Emmy Awards in the historic Pasadena Civic Auditorium,” said Bob Mauro, President, NATAS. “With an outstanding roster of nominees, we are looking forward to an extraordinary celebration honoring the craft and talent that represent the best of Daytime television.” “After receiving a record number of submissions, we are thrilled by this talented and gifted list of nominees that will be honored at this year’s Daytime Emmy Awards,” said David Michaels, SVP, Daytime Emmy Awards. “I am very excited that Michael Levitt is with us as Executive Producer, and that David Parks and I will be serving as Executive Producers as well. With the added grandeur of the Pasadena Civic Auditorium, it will be a spectacular gala that celebrates everything we love about Daytime television!” The Daytime Emmy Awards recognize outstanding achievement in all fields of daytime television production and are presented to individuals and programs broadcast from 2:00 a.m.-6:00 p.m.
    [Show full text]
  • Rebecca Jarvis, AB ‘03
    T H E U N I V E R S I T Y O F C H I C AG O | T h e C o l l e g e CLASS DAY 2 0 1 9 J U N E 14 PRESENTED BY: Rebecca Jarvis, AB ‘03 Hello class of 2019. Congratulations! I have good news and bad news. The bad news is that I’m not here to pay off your student loans. The good news is that I’m confident at least one of you out there today, will be able to make good on that class gift in the not so distant future. Thank you, Dean Boyer and Dean Ellison for the invitation to speak today. Thank you students for having me here to share in your class day celebrations! It is such an honor to be here with all of you. I graduated from the University of Chicago in 2003 with a degree in law, letters & society and economics. This campus is where i had some of the greatest debates of my life. Where my own assumptions and views were challenged daily. Where I learned how not what to think – truly one of the greatest gifts of a UChicago education. It’s also where I met my husband and made lifelong friends. But 16 years ago, sitting where you are, I still had so many questions. I was free! I was going to do big things. But how exactly would I do those big things? So I come here today with five hopefully valuable lessons, some more hard won than others, that I’ve learned on my post-UChicago journey.
    [Show full text]
  • Executive Branch Personnel Public Financial Disclosure Report (OGE Form 278E)
    Nominee Report | U.S. Office of Government Ethics; 5 C.F.R. part 2634 | Form Approved: OMB No. (3209-0001) (March 2014) Executive Branch Personnel Public Financial Disclosure Report (OGE Form 278e) Filer's Information DeVos, Elisabeth P ("Betsy") Secretary, Department of Education Other Federal Government Positions Held During the Preceding 12 Months: Names of Congressional Committees Considering Nomination: ● Committee on Health, Education, Labor, and Pensions Electronic Signature - I certify that the statements I have made in this form are true, complete and correct to the best of my knowledge. /s/ DeVos, Elisabeth P ("Betsy") [electronically signed on 01/19/2017 by DeVos, Elisabeth P ("Betsy") in Integrity.gov] Agency Ethics Official's Opinion - On the basis of information contained in this report, I conclude that the filer is in compliance with applicable laws and regulations (subject to any comments below). /s/ Goodridge-Keiller, Marcella, Certifying Official [electronically signed on 01/19/2017 by Goodridge-Keiller, Marcella in Integrity.gov] Other review conducted by /s/ Sprague, Marcia, Ethics Official [electronically signed on 01/19/2017 by Sprague, Marcia in Integrity.gov] U.S. Office of Government Ethics Certification /s/ Shaub, Walter M, Certifying Official [electronically signed on 01/19/2017 by Shaub, Walter M in Integrity.gov] 1. Filer's Positions Held Outside United States Government # ORGANIZATION NAME CITY, STATE ORGANIZATION POSITION HELD FROM TO TYPE 1 The Stow Company - Holland, Inc. See Endnote Holland, Corporation Chief Creative 5/2016 11/2016 Michigan Officer 2 The Stow Company - Holland, Inc. See Endnote Holland, Corporation Director 6/1994 11/2016 Michigan 3 RCB Main Floor, LLC (d/b/a "Reserve GR, See Endnote Grand Rapids, Corporation Director 3/2010 11/2016 LLC") Michigan 4 The Stow Company See Endnote Holland, Corporation Director 5/2010 11/2016 Michigan 5 Neurocore, LLC See Endnote Grand Rapids, Corporation Member/Manag 2/2009 11/2016 Michigan er 6 Windquest Group, Inc.
    [Show full text]
  • The Bleeding Edge: Theranos and the Growing Risk of an Unregulated Private Securities Market
    University of Miami Business Law Review Volume 28 Issue 2 Article 8 September 2020 The Bleeding Edge: Theranos and the Growing Risk of an Unregulated Private Securities Market Theodore O'Brien Follow this and additional works at: https://repository.law.miami.edu/umblr Part of the Business Organizations Law Commons, and the Securities Law Commons Recommended Citation Theodore O'Brien, The Bleeding Edge: Theranos and the Growing Risk of an Unregulated Private Securities Market, 28 U. Miami Bus. L. Rev. 404 (2020) Available at: https://repository.law.miami.edu/umblr/vol28/iss2/8 This Comment is brought to you for free and open access by the Journals at University of Miami School of Law Institutional Repository. It has been accepted for inclusion in University of Miami Business Law Review by an authorized editor of University of Miami School of Law Institutional Repository. For more information, please contact [email protected]. The Bleeding Edge: Theranos and the Growing Risk of an Unregulated Private Securities Market Theodore O’Brien* America’s securities laws and regulations, most of which were created in the early twentieth century, are increasingly irrelevant to the most dynamic emerging companies. Today, companies with sufficient investor interest can raise ample capital through private and exempt offerings, all while eschewing the public exchanges and the associated burdens of the initial public offering, public disclosures, and regulatory scrutiny. Airbnb, Inc., for example, quickly tapped private investors for $1 billion in April of 2020,1 adding to the estimated $4.4 billion the company had previously raised.2 The fundamental shift from public to private companies is evidenced by the so-called “unicorns,” the more than 400 private companies valued at more than $1 billion.
    [Show full text]
  • Theranos Phenomenon – Part 5: Theranos’ Presentation at the American Association for Clinical Chemistry Annual Conference 2016
    Clin Chem Lab Med 2016; 54(10): e313–e314 Letter to the Editor Eleftherios P. Diamandis* and Mario Plebani Theranos phenomenon – Part 5: Theranos’ presentation at the American Association for Clinical Chemistry Annual Conference 2016 DOI 10.1515/cclm-2016-0737 Master, two highly recognized and respected clinical Accepted for publication August 18, 2016; previously published chemists, who did a good job in asking pertinent ques- online August 30, 2016 tions to Ms. Holmes and her associates. In this respect, AACC lived up to the expectations of high standards and Keywords: diagnostics; new technologies. impartiality for this presentation. Holmes presented to a large and curious, if not To the Editor, hostile, audience. She avoided talking about Theranos’ past and the difficulties of her company [1–7]. She also The widely anticipated presentation of Theranos at the made it clear that her presentation would focus on the Annual Conference of the American Association for future, not the past, and she distanced herself from the Clinical Chemistry (AACC) was finally given on Monday, previous “Edison” instrument and introduced a new August 1st, 2016 at the Philadelphia Convention Center. analyzer named “MiniLab”. In the first part of her pres- This journal has followed the Theranos story closely over entation, Ms. Holmes described the engineering behind the last 2 years and provided frequent updates [1–4]. Eliza- the MiniLab and explained that it is a compact desktop beth Holmes, the Chief Executive of Theranos, presented device that houses a mini spectrophotometer, a mini- to an audience of over 2500 clinical chemists and other luminometer, and mini-flow-cytometer and a mini-PCR laboratory scientists, as well as to an impressive number machine, along with a centrifuge.
    [Show full text]